ABSTRACT Lipoxin A4 (LXA4), an endogenous anti-inflammatory and immunomodulatory mediator studied in many disease states, is recently appreciated as a potentially significant player in the

endometrium. This eicosanoid, synthesized from arachidonic acid via the action of lipoxygenase enzymes, is likely regulated in endometrial tissue during the menstrual cycle. Recent studies

revealed that LXA4 acts as an estrogen receptor agonist in endometrial epithelial cells, antagonizing some estrogen-mediated activities in a manner similar to the weak estrogen estriol, with

which it shares structural similarity. LXA4 may also be an anti-inflammatory molecule in the endometrium, though its precise function in various physiological and pathological scenarios

surgery or anti-hormone therapies that are contraceptive and associated with undesirable side effects. LXA4 may represent a potential therapeutic and further research to elucidate its

function in endometrial tissue and the peritoneal cavity will undoubtedly provide valuable insights. SIMILAR CONTENT BEING VIEWED BY OTHERS BIOSYNTHETIC PATHWAY FOR LEUKOTRIENES IS

STIMULATED BY LIPOPOLYSACCHARIDE AND CYTOKINES IN PIG ENDOMETRIAL STROMAL CELLS Article Open access 22 January 2025 N-ACETYLCYSTEINE STIMULATES ORGANELLE MALFUNCTION IN ENDOMETRIOTIC CELLS

VIA IFN-GAMMA SIGNALING Article Open access 29 April 2025 MACROPHAGES: A DOUBLE-EDGED SWORD IN FEMALE REPRODUCTION AND DISORDERS Article Open access 03 February 2025 INTRODUCTION The female

reproductive tract maintains an immune surveillance system similar to other mucosal surfaces, serving as the front line against pathogens. The uterus is unique given its roles in the

transport of male gametes and processing of seminal antigens. Immune crosstalk appears vital to the success of pregnancy and for tolerance of the fetal semi-allograft during implantation and

throughout gestation.1 In addition, in menstruating species such as humans and most primates, the cyclic shedding of the upper two-thirds of the endometrial surface requires rapid healing

and regeneration while maintaining those defenses and minimizing inflammatory responses.2 Ovulation, menstruation, implantation, and parturition all represent short-term inflammatory events3

limited by endogenous mediators that facilitate resolution of inflammation. Health is maintained by the balance between inflammation and metabolic and immune homeostasis, especially

important at mucosal surfaces such as the female reproductive tract. A disequilibrium in the inflammatory response to disease underlies many immune-mediated illnesses.4, 5, 6, 7, 8 Lipoxins

(LXs), as well as the more recently discovered Resolvins and Protectins, are specialized pro-resolving mediators essential for the resolution of inflammation9 In this review, we focus on a

molecule likely central to this balancing act in endometrial tissue, Lipoxin A4 (LXA4). LXA4 has been implicated as an anti-inflammatory mediator in human cycling endometrium and following

parturition.10, 11 The significance of LXA4 in normal endometrial physiology is difficult to gauge given the complexities of its signaling via different receptors with varying roles in

multiple cell types as well as the paucity of published data concerning its function (Figure 1). As an immune modulator, LXA4 has been shown in other systems to inhibit leukocyte

migration,12 leukotriene-induced responses, including vasoconstriction and chemotactic responses,13, 14 and mitogenic signals.15 Based on recent studies, LXA4 and related mediators are

likely to contribute to endometrial biology serving as a fulcrum between opposing forces to help maintain the balance required for tissue repair/wound healing during menstruation, tolerance

toward the nascent embryonic fetal allograft, maintenance of pregnancy, and the initiation and resolution of parturition. Additionally, as attenuated LXA4 production may contribute directly

to many inflammatory conditions and chronic disease states,16, 17, 18, 19, 20 dysregulation of LXA4 actions may significantly impact endometrial health and reproductive function. LIPOXIN A4

BIOSYNTHESIS AND LIPOXYGENASE METABOLITES In humans, the major LX biosynthetic pathways involve biosynthesis during specific cell:cell interactions and upon priming by cytokines21, 22 in the

vasculature and at mucosal boundaries, such as the endometrium. LX production occurs in a transcellular manner at sites of inflammation involving two different cell types such as epithelial

cells and neutrophils, for example. Three human lipoxygenase (LOX) enzymes, iron-containing enzymes that catalyze the hydroperoxidation of polyunsaturated fatty acids, have been cloned:

5-LOX, 12-LOX, and 15-LOX.23, 24 The sequential oxygenation of arachidonic acid results in LX formation. Aspirin triggers the generation of epimeric forms of LXs known as aspirin-triggered

LXs, such as 15-epi-LXA4,25 an attribute also shared by statins.26, 27 15-ALOX type 2, which exhibits a substrate preference for arachidonic acid converting it to

15S-hydroperoxyeicosatetraenoic acid (15S-HETE),24 is expressed in human endometrium.28 However, human 15-LOX isoforms exhibit allosteric product regulation,29 and the functional

significance of feedback loops _in vivo_ merits further investigation. Interleukin 13 (IL-13), is a potent inducer of 15-LOX gene expression and enzyme activity in human monocytes,30

requiring ERK1/2 MAPK (extracellular signal–regulated kinase 1/2/ mitogen-activated protein kinase) activation.31 IL-13 was also shown to induce the mouse homolog 12/15-LOX in monocytes

while IFN-γ (interferon gamma) inhibited expression and activity of this enzyme. IL-4 also induced 12/15-LOX in mouse myeloid cells.32 Both IL-4 and IL-13 are involved in differentiation of

monocytes into M2 macrophages, which exhibit an immunosuppressive phenotype when compared with M1 macrophages.33 12/15-LOX is a progesterone target gene in the mouse uterus, based on the

progesterone receptor knockout mouse model.34 There is precedent for hormonal regulation of this enzyme in mucosal tissues, such as the cornea, where 17β-estradiol (E2) downregulates 15-LOX

as well as LXA4 formation.35 In prostate cancer cells, glucocorticoids inhibit this enzyme,36 and in vascular smooth muscle cells aldosterone stimulates 12/15- LOX expression.37 In prostate

epithelial cells, peroxisome proliferator–activated receptor-gamma (PPAR-γ) interacts with the orphan receptor ROR-α to bind the 15-LOX promoter, providing a novel negative feedback

mechanism for 15-LOX and therefore LXA4 production.38 It remains to be seen whether such regulatory mechanisms are germane to the human endometrium. LXA4 levels are high at the end of the

menstrual cycle and then decline after menses.10 That is, coincidently, the time when IL-13 peaks during the normal menstrual cycle.39 As previously noted, estrogen-mediated inhibition of

this enzyme35 would fit well with the observation that LXA4 levels decline during the proliferative phase coincident with a rise in E2.10 The increase in LXA4 levels during pregnancy is

likely due to human chorionic gonadotropin, which promotes LXA4 release in the decidua of human endometrium.10 LOX metabolites have been implicated in reproductive function for over three

decades. One study in mice provided direct evidence of the importance of LOX metabolites during implantation.34 Using conditional PR knockout mice it was established that leukocyte and

epidermal 12/15-LOX were downstream targets of PR in uterine surface epithelium. At implantation, maximal induction of both 12/15-LOX enzymes was observed, with a parallel increase in the

eicosanoid metabolites 12-HETE, 15-HETE, and 13-HODE (13-(S)-hydroxyoctadecadienoic acid) in the uterus. Furthermore, leukocyte 12/15-LOX null mice exhibited impaired implantation and usage

of a 12/15-LOX inhibitor confirmed these results, leading to a significant reduction in implantation sites. 12-HETE, 15-HETE, and 13-HODE activated PPAR-γ in cell-based assays, and

Rosiglitazone, a PPAR-γ agonist, reversed the ability of a LOX inhibitor to inhibit implantation. This was the first demonstration that progesterone-induced synthesis of lipid mediators

derived from 12/15-LOX activity activated PPAR-γ and associated signaling pathways, serving to regulate implantation in the mouse. Indeed, LOX inhibitors have been shown to indirectly reduce

progesterone output in pregnancy.40 It will be instructive to determine the relative roles of these intermediate metabolites and whether LXA4 is also involved. LXA4 RECEPTORS Of the LX

family members, LXA4 is the best characterized. LXA4 inhibits immune cell recruitment, chemotaxis, adhesion, and transmigration, also attenuating pro-inflammatory cytokine production and

promoting resolution of inflammation, thereby serving as an important brake after injury or cellular insult _in vitro_ and _in vivo._ LXA4 modulates the function of both myeloid and

non-myeloid cell types.41, 42 This anti-inflammatory mediator appears promiscuous in its ability to bind and/or activate a number of both nuclear as well as membrane-bound receptors. LXA4

directly or indirectly activates various receptors, including a subclass of peptide receptors (CysLTs (cysteinyl leukotrienes)),15 as well as the G-protein-coupled receptor 32.43 LXA4

receptors also include formyl peptide receptor 2/LX A4 receptor (FPR2/ALX), another surface membrane G-protein-coupled receptor with diverse ligands,44, 45 the aryl hydrocarbon receptor

(AhR), a ligand-activated nuclear transcription factor,46 and more recently, estrogen receptor-alpha (ERα).28 Expression dynamics of the latter three receptors and LXA4 itself in endometrial

tissue are depicted in Figure 2. FPR2/ALX, the most studied receptor, to which LXA4 binds with high affinity,44, 45 is expressed by many different cell types, including neutrophils,

monocytes, natural killer cells as well as epithelial cells, where its expression is subject to differential regulation by cytokines.23, 47 A recent study on the molecular regulation of

FPR2/ALX reported that although monocytes expressed this receptor, their differentiation abrogated its expression, due to translation silencing.48 These results suggest that FPR2/ALX is of

limited relevance in tissue macrophage function, but further studies are required to delineate the functional significance of this observation. Recently, expression of FPR2/ALX in human

endometrium has been described.10 MacDonald _et al._10 found that FPR2/ALX mRNA expression is increased during the menstrual phase compared with proliferative, early- and mid-secretory phase

endometrium. As the endometrium has an upper (zona functionalis) and lower regenerative layer (zona basalis), FPR2/ALX receptor localization was found to be highest in the functionalis

layer, localized to glandular epithelial and stromal cells, as well as the cells lining the vasculature and associated immune cells. We observed a smiliar expression pattern (G. Canny,

unpublished data). In the first trimester of pregnancy, the decidua also exhibits high FPR2/ALX expression. Although LXA4 levels did not change in the peripheral circulation across the

menstrual cycle, serum levels were increased during early pregnancy, coincident with elevated FPR2/ALX levels. Another physiologically relevant receptor for LXA4 is AhR, which LXA4 was shown

to activate in murine hepatoma cells46 and murine dendritic cells.49 Interestingly, AhR has a role in immunity, with AhR-regulated genes being modulated by environmental toxins and

pro-inflammatory cytokines.50, 51 AhR-null mice succumb significantly faster to experimental toxoplasmosis than wild-type mice and displayed greater degrees of liver damage as well as

augmented serum levels of tumor necrosis factor-alpha (TNF-α), nitric oxide, and IgE but lower IL-10 production.52 Hematopoietic defects are also observed in AhR−/− mice and, though

classically considered important in mediating responses to environmental toxins, AhR is increasingly thought to be involved in immune responses.53 Of note, cyclo-oxygenase 2 (COX-2), the

rate limiting enzyme in prostaglandin E2 (PGE2) production is inducible by AhR ligands in various cell types.50 Although AhR is present in the human endometrium, where its expression

remained constant across the menstrual cycle,54 there have so far been no confirmatory reports demonstrating AhR activation by LXA4 in this tissue. LXA4 was recently characterized as an ER

ligand, stimulating expression of estrogen responsive genes, including alkaline phosphatase and PR, and inducing proliferation in human endometrial epithelial cells.28 Interestingly, LXA4

shares a high degree of structural similarity with the weak estrogen estriol (E3) made in large amounts by the placenta during pregnancy.55, 56 Consistent with the characteristics of a weak

ERα agonist, LXA4 also inhibited E2-mediated actions, as was previously shown for E357 and competed directly for ER binding with an IC50 of 46 nM. Arachidonic acid and 15S-HETE, the LX

precursors, as well as LXB4, an isomer, displayed minimal or no binding affinity, confirming the structural specificity. Acting in a manner similar to canonical ER signaling,58 LXA4 induced

ERα phosphorylation and targeted this receptor for degradation by the proteasome. Further confirmatory studies in mice revealed that LXA4 stimulated a uterotrophic response and induced

estrogen-responsive genes, including PR in uterine tissue _in vivo_. It should be noted that all the three above-mentioned receptors are promiscuous and subject to complex regulation in the

different endometrial cell types and at different stages of the menstrual cycle or during gestation. Since multiple receptors may be present in the same cell, well-controlled studies are

needed to fully explore potential crosstalk between these different classes of receptors and associated signaling systems, using physiologically relevant ligand concentrations and readouts.

ALTERNATIVE VIEWS ON LXA4 AND ESTROGEN ACTION The endometrium is a steroid hormone–dependent tissue and, in the humans, undergoes cyclic changes in response to the sequential actions of

estrogen and progesterone.59 Although the steroid hormone and gene regulation patterns of the normal menstrual cycle are beyond the scope of this review, endometrial changes have now been

well characterized in both health and disease.60, 61, 62, 63, 64, 65 One of the major factors in endometrial-related diseases is the imbalance between the actions of estrogen and

progesterone. Aside from the obvious example of endometrial cancer, endometriosis is a major health problem in women of reproductive age. The pathophysiology of endometriosis is intimately

linked with inflammation, a resistance to progesterone, exaggerated estrogen responsiveness, and/or increased ER signaling.66 Estrogen action in the endometrium in both health and disease is

an active area of research, and both estradiol and progesterone regulate the inflammatory events during menstruation and implantation.62, 67 It has long been known that estrogen upregulates

both ERα and PR in the human endometrium68, 69 as well as in primates and other mammals.70 Likewise, these studies have shown that progesterone downregulates both ERα and PR during the

secretory phase of the cycle.71 Early ERα immunohistochemistry data in human endometrium show that there is a marked reduction in all the cell types during the mid-secretory phase.72, 73,

74, 75 ER downregulated in luminal and glandular epithelium was associated with a decline in cell proliferation, except in the zona basalis.76, 77 In pregnancy, ERα is essentially absent due

to its down-modulation by progesterone.78, 79, 80, 81, 82 Interestingly, the timely loss of epithelial PR in the endometrium closely correlates well with the establishment of uterine

receptivity in humans as well as in most mammals studied.81, 83, 84, 85, 86, 87, 88 A delay in the opening of the window of implantation is associated with a correctable delay in the

down-modulation of epithelial PR.89 It has been suggested that E2 is unnecessary for normal endometrial secretory development.90 Failure of ERα downregulation could therefore, be an indirect

sign of progesterone resistance and has been reported in endometrial hyperplasia,75 endometriosis,91, 92, 93, 94, 95 and in the endometrium of women with polycystic ovary syndrome.64

Together, these data support the association between aberrant proliferation and the dysregulation of progesterone action, leading to proliferative disorders of the endometrium and a lack of

uterine receptivity. The interactions between eicosanoids, lipoxygenase metabolites, estrogens and nuclear receptors have not been well studied. E2 is the most potent estrogen produced in

the body and like other estrogens exerts its physiological actions though binding to and translocation of their receptors. ERs belong to the nuclear hormone receptor superfamily and function

as ligand-activated transcription factors.96 Estrogen signaling is largely mediated through two receptor isoforms: ERα and ERβ, initiating both genomic and non-genomic effects.97 Both of

these ERs are abundant in reproductive tissues, ERα being the dominant receptor within the adult uterus98 and ERβ of greater concentration in vascular cells or of interest in reproductive

tissues.74, 99, 100 Membrane ERs also exist, including the newly discovered G-protein-coupled receptor-30, recently studied in the endometrium.101 Although studies using ERα-deficient mice

have revealed the central role of this receptor in reproductive function at all levels of the hypothalamic–pituitary–gonadal axis,102 ERβ-mutant mice exhibit normal puberty but reduced

fecundity due to an impaired ovulation rate.103 G-protein-coupled receptor 30 is dispensable for fertility and does not mediate estrogenic responses in mouse reproductive organs.104 In

addition to ligand-induced activation, ERs are also subject to phosphorylation by various kinases that are themselves activated by inflammatory mediators or cytokines during endometrial

remodeling.105 TNFα was recently shown to activate ER and induce E2-regulated genes in endometrial epithelial cells,106 indicating immunoendocrine crosstalk occurs in inflammatory

endometrial conditions. The significance of membrane-initiated steroid signaling107 in these contexts remains to be elucidated, but alternations in the inflammatory milieu could dramatically

alter the actions of estrogens, their metabolites, or other ligands, such as LXA4. A model of LXA4-mediated actions in endometrial tissue would depend on temporal and spatial availability

of available ligands and receptors (Figure 2). The increased level of FPR2/ALX at menses,10 potentially coinciding with increased local LXA4 production due to immunocyte influx,108 could

contribute to the early burst of endometrial healing and growth that occur at a time when endogenous E2 is relatively low. In addition, higher ERα expression noted in the basalis glands and

stroma provides a potential target for LXA4 at menses when estrogen levels are at their nadir. Whether LXA4 initiates endometrial regeneration and healing at this time merits investigation.

The zona basalis in primates undergoes cellular proliferation in the mid-to-late secretory phase.76, 77 Given the reduced level of estrogen in the secretory phase and the virtual absence of

ERα in endometrial epithelium and stroma of the zona functionalis at the time of implantation,73, 74 it is possible that LXA4 has a role in that early proliferative activity seen in the

basal glands, thought to be an important aspect of endometrial regeneration. ERβ, on the other hand, present in vascular components of the endometrium and placenta109 or FPR2/ALX, present in

the decidualized stroma, immune cells in the vasculature, and in the myometrium of human uterus,10 may also be targets for LXA4 exerting anti-inflammatory actions to support the ongoing

pregnancy (Figure 1). Pregnancy is, by necessity, an immunocompromised state, whereby the growing fetus is tolerated while maintaining maternal immunity.110 LXA4, acting as an ERα agonist as

previously observed in human endometrial epithelial cells,28 may participate in the downregulation of ERα observed in the late secretory phase. Loss of ERα is also essential in the

pre-implantation uterus of most mammalian species. Finally, AhR is a known receptor for LXA4 and is present in the endometrium of secretory endometrium.54 Considering the putative role of

AhR as a suppressor of ERα signaling via several mechanisms,111, 112 it could be speculated that LXA4 might come into play in certain circumstances. Although we showed that AhR does not seem

to be involved in LXA4 signaling in human endometrial epithelial cells,28 actions involving this receptor in other cell types under different circumstances or _in vivo_ cannot be excluded.

MACROPHAGES AS A LXA4 TARGET Innate immune cells, including macrophages are a major target of LXA4-mediated bioactivities (Figure 1). Given that leukocytes represent 30–40% of the

endometrial cell population113 leading to LXA4 transcellular biosynthesis, this lipid mediator likely has a role in homeostatic processes. Macrophages and uterine natural killer cells are

abundant in the endometrial stroma and are found through most of the menstrual cycle. Sex hormones regulate macrophage distribution in this tissue. Macrophage numbers increase in the

premenstrual endometrial stroma, coinciding with falling estrogen and progesterone levels due to the demise of the corpus luteum.114 Macrophages, through their ability to produce matrix

metalloproteinases (MMPs), are involved in tissue remodeling and are intimately linked with both menstruation108, 113, 115 and pregnancy.116, 117 It is noteworthy that LXA4 and its analogs

decrease MMP expression and activity in many different cell types118, 119 and also in peritoneal fluid cells in a mouse model of endometriosis,120, 121 of which macrophages comprise a major

component. In the first trimester of pregnancy, macrophages constitute the second most predominant leukocyte population (<30%) of decidual cells after decidual natural killer cells

(<70%)122 and differentiate from monocytes. Decidual macrophages function in the removal of apoptotic bodies, uterine vascular remodeling, immune tolerance towards fetal antigens,

immunity against external pathogens and cervical ripening and recovery123 and elicit immunosuppressive and anti-inflammatory responses. Apoptotic body clearance results in the expression of

anti-inflammatory cytokines such as IL-4, IL-6, and IL-10, with protective effects on trophoblast survival. Efferocytosis is a process whereby phagocytes engulf apoptotic cells and the

latter impact macrophage phenotype. The newly discovered pro-resolving macrophage subset, Mres, appear later in the resolution program.124 LXA4 promotes the engulfment of apoptotic

neutrophils, and tissue fragments, by macrophages, a process essential to the resolution of inflammation125, 126 and the re-establishment of tissue integrity post-menstruation.113 The

domains of immunology and metabolism are converging, providing insights into a variety of physiological and pathological states.127 The previously mentioned ALOX metabolites and PPAR

ligands, as well as T helper type 2 (Th2) cytokines and specialized pro-resolution mediators drive temporarily distinct metabolic shifts and effector functions in macrophages.128 Recent

studies have implicated ERα in macrophage function and metabolism and demonstrated a protective role for this receptor on hematopoetic/myeloid cells in atherosclerosis-related

inflammation.129 As alluded to above, estrogens are linked with macrophage recruitment into the endometrium and are clearly implicated in immune responses. The role of ERα in LXA4-mediated

regulation of macrophage function in the endometrium and peritoneal cavity awaits elucidation. ENDOMETRIOSIS: A COMPLEX DISEASE FOR WHICH IMPROVED TREATMENT MODALITIES ARE NECESSARY

Endometriosis, an inflammatory, estrogen-stimulated disease affects approximately 10% of women of reproductive age, and it is estimated that up to 80% of unexplained infertility is

attributable to this condition.65, 130, 131 First described by Daniel Schroen in 1690, several theories have been proposed but none fully explain the etiology. The most well accepted is

Sampson’s132 theory of retrograde menstruation, whereby fragments of menstrual endometrium pass backward through the fallopian tubes and into the peritoneal cavity where they implant and

persist. The eutopic endometrium of women with endometriosis becomes altered as shown in the baboon model,133, 134 with increased estrogen activity, cellular proliferation, and progesterone

resistance.66 The biological mechanisms linking endometriotic lesions to these endometrial alterations remains uncertain and controversial.135 Although progesterone resistance and estrogen

dominance likely contribute to the pathophysiology and survival of ectopic lesions,134, 136, 137 they probably contribute to infertility as well.66, 95, 134 There is overwhelming evidence

that normal immune responses, which serve to promote fertility and immunotolerance, are altered in women with endometriosis, with inflammatory changes in the intrauterine milieu, the

peritoneal cavity, and systemic circulation.65, 138, 139, 140 Cellular proliferation and inflammation are intimately linked via both hormonal and inflammatory mediators such as IL-1, TNF-α,

PGE2, or E2, which, in turn, induce growth factors, cytokines, and chemokines that promote inflammation, cellular proliferation, and angio- and lymphangiogenesis.141, 142 Estrogens directly

regulate the endometrial expression of many cytokines and growth factors as well as their receptors thereby contributing to endometriotic lesion growth.140 Conversely, TNF-α increases

estrogen biosynthesis by human endometrial glandular cells and directs estrogen metabolism towards more hormonally active and carcinogenic metabolites.143 Crosstalk between the immune and

endocrine systems therefore clearly contributes to endometriosis pathology. Dysregulations in local immune mediator concentration and/or signaling leads to increased inflammation in the

peritoneal cavity and the resulting systemic changes could conceivably alter the number and profile of immune cells that traffic to the endometrium. Dysfunction in macrophage-mediated

phagocytosis of cells that are transported into the peritoneal cavity by retrograde menstruation is considered an important factor in the development of endometriosis. PGE2 diminished human

macrophage-mediated phagocytosis by downregulating the scavenger receptor and lipid transporter CD36, thought to have a significant role in macrophage-mediated phagocytosis, and also

increased endometriotic lesion size in mice.144 There is some evidence that macrophages in endometriosis are M2 polarized, also known as alternatively activated macrophages, in human, mouse,

and primate.145, 146 In the former study, macrophages in both inflammatory liquid and ectopic lesions were M2 polarized in endometriosis patients but not in control subjects. Adoptive

transfer of alternatively activated macrophages dramatically enhanced endometriotic lesion growth in mice, and M1 polarized, inflammatory macrophages protected mice from disease

establishment. It should be noted, however, that human macrophages markers are less well characterized than murine cells and extracellular marker analysis should ideally be coupled with that

of pertinent effector molecules. Several different types of macrophages subsets have been described, and more are likely yet to be discovered. Macrophages display a phenotypic plasticity as

a function of environmental cues, including cytokines and growth factors.33 LXA4 promotes M2 polarization _in vitro_.147 Further studies are necessary to determine the precise macrophage

subsets in endometrial tissue and peritoneal fluid and whether their polarization contributes to pathological responses. In endometriosis, establishment of an immunotolerant (Th2/Treg

(regulatory T cell)) environment139, 148, 149 appears to be replaced by an inflammatory Th1/Th17 immune response.1, 150 Retinoids, vitamin A derivatives that mediate diverse physiological

functions, exert their pleiotropic effects through the interaction with nuclear receptors, defined as retinoic acid receptors and retinoid X receptors (RXRs).151 Retinoic acid (RA) as an

important intermediary down-stream effector of progesterone action is also involved in immune cell programming.152 Retinol-binding proteins are under the regulation of progesterone in

primates153 and human endometrium. Among six retinoid receptors examined, RXRγ immunoreactivity was exclusively detected in the epithelial cells of the secretory phase endometrium but not of

the proliferative phase.154 These data indicate that its expression is induced by progesterone. It is noteworthy that nuclear receptors such as RXR and PPAR-γ heterodimerize and it seems

that these dimers provide cells such as macrophages with a coordinated and inter-related network of transcriptional regulators for interpreting local metabolic changes resulting in subtype

differentiation.152 T-cell differentiation is altered toward an inflammatory phenotype in endometriosis, RA and PPAR-γ being essential for Treg differentiation.155, 156 Inflammatory changes,

including augmented IL-6 and IL-23, promotes conversion of Tregs to Th17 cells.157 Of note, PPAR-γ selectively inhibits Th17 differentiation of CD4+ T-cells.156 As such, several nuclear

receptors likely impact physiological and pathological processes in endometrial tissue, conceivably involving LXA4. LXA4 inhibits endometriosis progression in the mouse preclinical

model.121, 158 As shown for LXA4 or a stable analog,121, 159 pretreatment with a combination of progesterone, RA, and TGFβ greatly attenuates MMPs expression and reduces endometriotic lesion

growth.160 Interestingly, LXA4 also suppresses phorbol myristate acetate–induced expression of the inflammatory cytokines IL-6 and IL-8 in human decidua tissue10 and attenuates CCL2, IL-6

and inhibit nuclear factor (NF)-κB and Akt pathways in other animal models of inflammation.161, 162 These observations may constitute mechanisms underlying its beneficial effects in

preclinical endometriosis models but also raise the question whether LXA4 is a down-stream effector of progesterone and RA actions. Interestingly, a recent paper demonstrated the protective

effect of fish oil in endometriosis in a chimeric model where human endometrial tissue was injected into the peritoneum of nude mice.163 Mice administered fish oil exhibited fewer leukocytes

within lesions and less collagen deposition at adhesions indicating that dietary intervention may prevent postsurgical adhesion development. These effects may well be due to the formation

of pro-resolving lipid mediators such as resolvins and protectins, metabolized from omega 3 fatty acids.9 Hormone production, signaling, and metabolism are significantly perturbed and

progesterone resistance comprises part of the pathology.66, 164 Treatment of endometrial epithelial cells with 2,3,7,8-tetrachlorodibenzo_-p-_dioxin, a potent AhR ligand, altered the

expression of PR-B165 as a possible mechanism of progesterone resistance, this environmental toxin having been implicated in endometriosis development. PR-B in the uterus can exert an

anti-inflammatory action, opposing PR-A.166 PR-A induced inflammatory cytokines IL-8-, IL-1β-, and NF-κB-regulated genes, while PR-B induced FKBP52 and NFKB1A, an inhibitor of the NF-κB

pathway. FKBP52 has been shown to be decreased in endometriosis.167, 168 This PR chaperone protein is required for proper progesterone-mediated actions and its reduction in this disease may

be a major determinant in progesterone resistance.136 Progesterone resistance in endometriosis is associated with a decrease in RA activity;169 RA uptake protein STRA6 and cellular

RA-binding protein 2 (both progesterone-regulated genes) are reduced in eutopic endometrium in endometriosis. Women with unexplained pregnancy loss also have reduced RA-binding protein 2.170

A recent study showed that RA treatment reduced endometriosis lesion size in the mouse model, with decreased IL-6 and MCP-1,171 actions similar to those elicited by LXA4. RA acts in concert

with progesterone and PPAR-γ to limit inflammation; specifically inhibiting the expression of the pleiotrophic cytokine IL-6 at the promoter, limiting its production172 along with IFN-γ,

while reduced RA action results in augmented IL-6 expression.169 In endometriosis, stromal cells produce increased IL-6 in response to IL-1β.173 Estrogen’s ability to inhibit LXA4 production

in other mucosal tissues35 has important potential implications for endometriosis. As progesterone opposes estrogen action, progesterone resistance leads to increased estrogenicity in

eutopic and ectopic endometrial tissue, perhaps also in the peritoneal compartment. ERα itself is one of the best recognized markers of progesterone resistance. In endometriosis, ERα is more

abundant and displays a failure of downregulation in eutopic95 and ectopic tissue.174, 175 The underlying reasons are unknown but could include aberrant modification and/or targeting to the

proteasome, as part of abnormal responses to this hormone, or could be linked to progesterone resistance. ERα is more important than ERβ in endometriosis lesion development in mice, as

recently demonstrated in an immunocompetent model.176 In this study, ERα-null lesions were associated with increased inflammation, it is therefore tempting to speculate that endogenous ERα

ligands mediate this effect. However, data from human studies showed that ERβ is overexpressed in endometriotic lesions and may have a role in the pathophysiology. A high ERβ-to-ERα ratio in

endometriotic stromal cells is associated with suppressed PR and augmented COX-2 levels contributing to progesterone resistance and inflammation.100 High levels of ERβ result in suppressed

ERα expression and estradiol responses in endometrial and endometriotic stromal cells.174 We have recently demonstrated increased ERα and ERβ expression in ectopic and peritoneal tissue of

patients with peritoneal endometriosis compared with control subjects, with a particularly marked elevation in ERβ observed,175 as has also been reported for ovarian endometriosis.164 The

respective role of stromal and epithelial cells within lesions as well as the myeloid cells in the peritoneal cavity, and their immune and metabolic products, remains unclear. ER crosstalk

and regulation is likely to be crucial. This complex area of biology necessitates further research and differences between murine models and the human pathology likely exist. Advances in

understanding of the latter will necessitate standardized, well-designed studies and facilitate the discovery of relevant biomarker panels, which will hopefully serve to decrease the long

delay before diagnosis.177, 178, 179 Estrogen production is also increased in endometriosis,180 likely influenced by the inflammatory environment.181 Here, the COX-2-derived eicosanoid PGE2,

as a potent inducer of aromatase and Steroidogenic acute regulatory protein expression, has a pivotal role.182 Furthermore, estrogen degradation is regulated by progesterone and defective

in progesterone resistance.183 Estrogen may be pro-inflammatory in endometriosis184 and contributes to the pathophysiology of the disease as a mitogen causing aberrant proliferation185 and

inhibition of apoptosis,186 decreasing the tumor-suppressor phosphatase and tensin homolog deleted on chromosome 10 via NF-κB dependent pathways.187 Defective immunity and decreased

production or activity of anti-inflammatory mediators such as LXA4 could account for the development of sustained inflammation seen in the reproductive tract and peritoneal fluid188 of

endometriosis patients. Alterations in endometrial stroma have long been noted,173, 189 including an exaggerated response to IL-1β and TNF-α, resulting in excessive production of the

inflammatory cytokines ENA-78 (epithelial neutrophil–activating peptide-78), IL-6, and IL-8.190 Other inflammatory cytokines, including IL-17, increase IL-8 secretion and expression of

COX-2191 and aromatase,192, 193 making this pathway an attractive therapeutic target.194 LXA4 production is induced by IL-13 in monocytes,30 and IL-13 is regulated during the menstrual

cycle, with expression induced by ovarian steroid hormones and cytokines.39, 195 Studies on micro(mi)RNA expression196, 197 have revealed a wide variety of changes in this disease. Let-7

miRNA was one of those most upregulated in the endometrium of women with endometriosis196 and intruigingly, a let-7 miRNA polymorphism has been associated with endometriosis.198 Let-7 miRNAs

inhibit IL-13 expression.199 Current treatments are directed toward surgical excision of ectopic endometrial tissue, and symptom alleviation, usually by targeting hormones or their

receptors. Upon cessation of treatment, endometriosis frequently recurs. Furthermore, surgery can result in adhesion development, which can also lead to chronic pelvic pain and

infertility.200 Novel approaches are therefore necessary as traditional therapies, the majority of which target hormones or their receptors, have been hampered by poor bioavailability,

undesirable side effects, and a negative impact on fertility.201, 202 As inflammation underlies the major endometriosis-associated symptoms, notably infertility and pain, a well-tolerated

immunomodulatory therapy targeting inflammatory changes associated with this disease could improve symptoms without the untoward side-effects of existing treatments. As detailed above, LXA4

exerts a protective effect in preclinical endometriosis models, through anti-inflammatory and anti-angiogenic mechanisms.120, 121, 159 Importantly, cycling remained unchanged, indicating

that LXA4 does not alter ovarian function. In conclusion, complex and interrelated pathways link the immune response to steroid hormone actions. Studies on endometrial function and

endometriosis confirm the importance of the balance between inflammation and its resolution. Pregnancy itself is dependent on this compromise between self-defense and beneficence.110 Future

research efforts will be needed to clarify the functional ramifications of LXA4 as an anti-inflammatory modulator and ER agonist. As a molecule with multiple modes of action and the ability

to mitigate some E2-mediated responses,28 as well as potentially divergent actions on myeloid and non-myeloid cell types, revelations on its role in endometrial physiology and metabolism

will likely identify therapeutic opportunities. Indeed, research in the emerging domain of immuno-metabolism is predicted to generate key insights into reproductive biology and disease.

REFERENCES * Guerin, L.R., Prins, J.R. & Robertson, S.A. Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment? _Hum. Reprod. Update_ 15, 517–535

(2009). Article  CAS  PubMed  PubMed Central  Google Scholar  * Evans, J. & Salamonsen, L.A. Inflammation, leukocytes and menstruation. _Rev. Endocr. Metab. Disord._ 13, 277–288 (2012).

Article  CAS  PubMed  Google Scholar  * Jabbour, H.N., Sales, K.J., Catalano, R.D. & Norman, J.E. Inflammatory pathways in female reproductive health and disease. _Reproduction_ 138,

903–919 (2009). Article  CAS  PubMed  Google Scholar  * Fierro, I.M., Kutok, J.L. & Serhan, C.N. Novel lipid mediator regulators of endothelial cell proliferation and migration:

aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). _J. Pharmacol. Exp. Ther._ 300, 385–392 (2002). Article  CAS  PubMed  Google Scholar  * Gewirtz, A.T., Neish, A.S. & Madara, J.L.

Mechanisms of active intestinal inflammation and potential down-regulation via lipoxins. _Adv. Exp. Med. Biol._ 507, 229–236 (2002). Article  CAS  PubMed  Google Scholar  * Kantarci, A.

& Van Dyke, T.E. Lipoxins in chronic inflammation. _Crit. Rev. Oral Biol. Med._ 14, 4–12 (2003). Article  PubMed  Google Scholar  * Kowal-Bielecka, O., Kowal, K., Distler, O. & Gay,

S. Mechanisms of disease: leukotrienes and lipoxins in scleroderma lung disease--insights and potential therapeutic implications. _Nat. Clin. Pract. Rheumatol._ 3, 43–51 (2007). Article  CAS

  PubMed  Google Scholar  * Machado, F.S. & Aliberti, J. Lipoxins as an immune-escape mechanism. _Adv. Exp. Med. Biol._ 666, 78–87 (2009). Article  CAS  PubMed  Google Scholar  *

Bannenberg, G. & Serhan, C.N. Specialized pro-resolving lipid mediators in the inflammatory response: an update. _Biochim. Biophys. Acta._ 1801, 1260–1273 (2010). Article  CAS  PubMed 

PubMed Central  Google Scholar  * Macdonald, L.J., Boddy, S.C., Denison, F.C., Sales, K.J. & Jabbour, H.N. A role for lipoxin A(4) as an anti-inflammatory mediator in the human

endometrium. _Reproduction_ 142, 345–352 (2011). Article  CAS  PubMed  PubMed Central  Google Scholar  * Maldonado-Perez, D., Golightly, E., Denison, F.C., Jabbour, H.N. & Norman, J.E. A

role for lipoxin A4 as anti-inflammatory and proresolution mediator in human parturition. _FASEB J._ 25, 569–575 (2011). Article  CAS  PubMed  Google Scholar  * Hedqvist, P., Raud, J.,

Palmertz, U., Haeggstrom, J., Nicolaou, K.C. & Dahlen, S.E. Lipoxin A4 inhibits leukotriene B4-induced inflammation in the hamster cheek pouch. _Acta. Physiol. Scand._ 137, 571–572

(1989). Article  CAS  PubMed  Google Scholar  * Lee, T.H., Lympany, P., Crea, A.E. & Spur, B.W. Inhibition of leukotriene B4-induced neutrophil migration by lipoxin A4:

structure-function relationships. _Biochem. Biophys. Res. Commun._ 180, 1416–1421 (1991). Article  CAS  PubMed  Google Scholar  * Badr, K.F., DeBoer, D.K., Schwartzberg, M. & Serhan,

C.N. Lipoxin A4 antagonizes cellular and _in vivo_ actions of leukotriene D4 in rat glomerular mesangial cells: evidence for competition at a common receptor. _Proc. Natl. Acad. Sci. USA_

86, 3438–3442 (1989). Article  CAS  PubMed  PubMed Central  Google Scholar  * McMahon, B., Mitchell, D., Shattock, R., Martin, F., Brady, H.R. & Godson, C. Lipoxin, leukotriene, and PDGF

receptors cross-talk to regulate mesangial cell proliferation. _FASEB J._ 16, 1817–1819 (2002). CAS  PubMed  Google Scholar  * Celik, G.E., Erkekol, F.O., Misirligil, Z. & Melli, M.

Lipoxin A4 levels in asthma: relation with disease severity and aspirin sensitivity. _Clin. Exp. Allergy_ 37, 1494–1501 (2007). CAS  PubMed  Google Scholar  * Merched, A.J., Ko, K.,

Gotlinger, K.H., Serhan, C.N. & Chan, L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. _FASEB J._ 22, 3595–3606

(2008). Article  CAS  PubMed  PubMed Central  Google Scholar  * O’Meara, Y.M. & Lipoxins, H.R. leukocyte recruitment and the resolution phase of acute glomerulonephritis. _Kidney Int.

Suppl._ 58, S56–S61 (1997). PubMed  Google Scholar  * Vachier, I. _et al_. Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. _J. Allergy Clin.

Immunol._ 115, 55–60 (2005). Article  CAS  PubMed  Google Scholar  * Marx, J.L. Cytokines are two-edged swords in disease. _Science_ 239, 257–258 (1988). Article  CAS  PubMed  Google Scholar

  * Sala, A., Folco, G. & Murphy, R.C. Transcellular biosynthesis of eicosanoids. _Pharmacol. Rep._ 62, 503–510 (2010). Article  CAS  PubMed  PubMed Central  Google Scholar  *

Papayianni, A., Serhan, C.N., Phillips, M.L., Rennke, H.G. & Brady, H.R. Transcellular biosynthesis of lipoxin A4 during adhesion of platelets and neutrophils in experimental immune

complex glomerulonephritis. _Kidney Int._ 47, 1295–1302 (1995). Article  CAS  PubMed  Google Scholar  * Serhan, C.N. Controlling the resolution of acute inflammation: a new genus of dual

anti-inflammatory and proresolving mediators. _J. Periodontol._ 79, 1520–1526 (2008). Article  CAS  PubMed  Google Scholar  * Brash, A.R., Boeglin, W.E. & Chang, M.S. Discovery of a

second 15S-lipoxygenase in humans. _Proc. Natl. Acad. Sci. USA_ 94, 6148–6152 (1997). Article  CAS  PubMed  PubMed Central  Google Scholar  * Claria, J. & Serhan, C.N. Aspirin triggers

previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. _Proc. Natl. Acad. Sci. USA_ 92, 9475–9479 (1995). Article  CAS  PubMed  PubMed Central  Google

Scholar  * Birnbaum, Y. _et al_. Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat

heart. _Prostaglandins Other Lipid Mediat._ 83, 89–98 (2007). Article  CAS  PubMed  Google Scholar  * Planaguma, A. _et al_. Lovastatin decreases acute mucosal inflammation via

15-epi-lipoxin A4. _Mucosal Immunol._ 3, 270–279 (2010). Article  CAS  PubMed  PubMed Central  Google Scholar  * Russell, R., Gori, I., Pellegrini, C., Kumar, R., Achtari, C. & Canny,

G.O. Lipoxin A4 is a novel estrogen receptor modulator. _FASEB J._ 25, 4326–4337 (2011). Article  CAS  PubMed  Google Scholar  * Wecksler, A.T., Kenyon, V., Deschamps, J.D. & Holman,

T.R. Substrate specificity changes for human reticulocyte and epithelial 15-lipoxygenases reveal allosteric product regulation. _Biochemistry_ 47, 7364–7375 (2008). Article  CAS  PubMed 

Google Scholar  * Nassar, G.M., Morrow, J.D., Roberts, L.J., Lakkis, F.G. & Badr, K.F. Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. _J. Biol. Chem._ 269,

27631–27634 (1994). Article  CAS  PubMed  Google Scholar  * Bhattacharjee, A., Mulya, A., Pal, S., Roy, B., Feldman, G.M. & Cathcart, M.K. Monocyte 15-lipoxygenase gene expression

requires ERK1/2 MAPK activity. _J. Immunol._ 185, 5211–5224 (2010). Article  CAS  PubMed  Google Scholar  * Yang, X.Y. _et al_. Interleukin (IL)-4 indirectly suppresses IL-2 production by

human T lymphocytes via peroxisome proliferator-activated receptor gamma activated by macrophage-derived 12/15-lipoxygenase ligands. _J. Biol. Chem._ 277, 3973–3978 (2002). Article  CAS 

PubMed  Google Scholar  * Sica, A. & Mantovani, A. Macrophage plasticity and polarization: _in vivo_ veritas. _J. Clin. Invest._ 122, 787–795 (2012). Article  CAS  PubMed  PubMed Central

  Google Scholar  * Li, Q., Cheon, Y.P., Kannan, A., Shanker, S., Bagchi, I.C. & Bagchi, M.K. A novel pathway involving progesterone receptor, 12/15-lipoxygenase-derived eicosanoids, and

peroxisome proliferator-activated receptor gamma regulates implantation in mice. _J. Biol. Chem._ 279, 11570–11581 (2004). Article  CAS  PubMed  Google Scholar  * Wang, S.B., Hu, K.M.,

Seamon, K.J., Mani, V., Chen, Y. & Gronert, K. Estrogen negatively regulates epithelial wound healing and protective lipid mediator circuits in the cornea. _FASEB J._ 26, 1506–1516

(2012). Article  CAS  PubMed  PubMed Central  Google Scholar  * Feng, Y., Bai, X., Yang, Q., Wu, H. & Wang, D. Downregulation of 15-lipoxygenase 2 by glucocorticoid receptor in prostate

cancer cells. _Int. J. Oncol._ 36, 1541–1549 (2010). Article  CAS  PubMed  Google Scholar  * Limor, R. _et al_. Aldosterone up-regulates 12- and 15-lipoxygenase expression and LDL oxidation

in human vascular smooth muscle cells. _J. Cell. Biochem._ 108, 1203–1210 (2009). Article  CAS  PubMed  Google Scholar  * Subbarayan, V. _et al_. 15-Lipoxygenase-2 gene regulation by its

product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma. _Oncogene_ 25, 6015–6025 (2006). Article 

CAS  PubMed  Google Scholar  * Chegini, N., Ma, C., Roberts, M., Williams, R.S. & Ripps, B.A. Differential expression of interleukins (IL) IL-13 and IL-15 throughout the menstrual cycle

in endometrium of normal fertile women and women with recurrent spontaneous abortion. _J. Reprod. Immunol._ 56, 93–110 (2002). Article  CAS  PubMed  Google Scholar  * Sato, K., Chisaka, H.,

Okamura, K. & Challis, J.R. Effect of the interaction between lipoxygenase pathway and progesterone on the regulation of hydroxysteroid 11-Beta dehydrogenase 2 in cultured human term

placental trophoblasts. _Biol. Reprod._ 78, 514–520 (2008). Article  CAS  PubMed  Google Scholar  * Serhan, C.N., Chiang, N. & Van Dyke, T.E. Resolving inflammation: dual

anti-inflammatory and pro-resolution lipid mediators. _Nat. Rev. Immunol._ 8, 349–361 (2008). Article  CAS  PubMed  PubMed Central  Google Scholar  * Serhan, C.N. Resolution phase of

inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. _Annu. Rev. Immunol._ 25, 101–137 (2007). Article  CAS  PubMed  Google Scholar  *

Krishnamoorthy, S. _et al_. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. _Proc. Natl. Acad. Sci. USA_ 107, 1660–1665 (2010). Article  CAS  PubMed  PubMed

Central  Google Scholar  * Fiore, S., Romano, M., Reardon, E.M. & Serhan, C.N. Induction of functional lipoxin A4 receptors in HL-60 cells. _Blood_ 81, 3395–3403 (1993). Article  CAS 

PubMed  Google Scholar  * Fiore, S., Maddox, J.F., Perez, H.D. & Serhan, C.N. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. _J. Exp. Med._ 180,

253–260 (1994). Article  CAS  PubMed  Google Scholar  * Schaldach, C.M., Riby, J. & Bjeldanes, L.F. Lipoxin A4: a new class of ligand for the Ah receptor. _Biochemistry_ 38, 7594–7600

(1999). Article  CAS  PubMed  Google Scholar  * Chiang, N. _et al_. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions _in vivo_. _Pharmacol. Rev._ 58, 463–487

(2006). Article  CAS  PubMed  Google Scholar  * Waechter, V. _et al_. Characterization of the promoter and the transcriptional regulation of the lipoxin A4 receptor (FPR2/ALX) gene in human

monocytes and macrophages. _J. Immunol._ 188, 1856–1867 (2012). Article  CAS  PubMed  Google Scholar  * Machado, F.S. _et al_. Anti-inflammatory actions of lipoxin A4 and aspirin-triggered

lipoxin are SOCS-2 dependent. _Nat. Med._ 12, 330–334 (2006). Article  CAS  PubMed  Google Scholar  * Vondracek, J., Umannova, L. & Machala, M. Interactions of the aryl hydrocarbon

receptor with inflammatory mediators: beyond CYP1A regulation. _Curr. Drug Metab._ 12, 89–103 (2011). Article  CAS  PubMed  Google Scholar  * Stockinger, B., Hirota, K., Duarte, J. &

Veldhoen, M. External influences on the immune system via activation of the aryl hydrocarbon receptor. _Semin. Immunol._ 23, 99–105 (2011). Article  CAS  PubMed  Google Scholar  * Sanchez,

Y. _et al_. The unexpected role for the aryl hydrocarbon receptor on susceptibility to experimental toxoplasmosis. _J. Biomed. Biotechnol._ 2010, 505694 (2010). Article  PubMed  PubMed

Central  CAS  Google Scholar  * Stevens, E.A., Mezrich, J.D. & Bradfield, C.A. The aryl hydrocarbon receptor: a perspective on potential roles in the immune system. _Immunology_ 127,

299–311 (2009). Article  CAS  PubMed  PubMed Central  Google Scholar  * Igarashi, T. _et al_. Expression of Ah receptor and dioxin-related genes in human uterine endometrium in women with or

without endometriosis. _Endocr. J._ 46, 765–772 (1999). Article  CAS  PubMed  Google Scholar  * Kaijser, M., Granath, F., Jacobsen, G., Cnattingius, S. & Ekbom, A. Maternal pregnancy

estriol levels in relation to anamnestic and fetal anthropometric data. _Epidemiology_ 11, 315–319 (2000). Article  CAS  PubMed  Google Scholar  * Peter, M., Dorr, H.G. & Sippell, W.G.

Changes in the concentrations of dehydroepiandrosterone sulfate and estriol in maternal plasma during pregnancy: a longitudinal study in healthy women throughout gestation and at term.

_Horm. Res._ 42, 278–281 (1994). Article  CAS  PubMed  Google Scholar  * Clark, J.H. & Markaverich, B.M. The agonistic and antagonistic actions of estriol. _J. Steroid Biochem._ 20,

1005–1013 (1984). Article  CAS  PubMed  Google Scholar  * McDonnell, D.P. & Norris, J.D. Connections and regulation of the human estrogen receptor. _Science_ 296, 1642–1644 (2002).

Article  CAS  PubMed  Google Scholar  * Strauss, J.F. & Lessey, B.A. The structure, function, and evaluation of the female reproductive tract In: Strauss J.F. III, Barbieri R.L., eds)

_Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management_, Saunders Elsevier: Philadelphia, PA, USA, (2009) 191–233. Google Scholar  * Critchley, H.O. &

Saunders, P.T.K. Hormone receptor dyamics in a receptive human endometrium. _Reprod. Sci._ 16, 191–198 (2009). Article  CAS  PubMed  Google Scholar  * Maybin, J.A., Critchley, H.O. &

Jabbour, H.N. Inflammatory pathways in endometrial disorders. _Mol. Cell. Endocrinol._ 335, 42–51 (2011). Article  CAS  PubMed  Google Scholar  * King, A.E. & Critchley, H.O. Oestrogen

and progesterone regulation of inflammatory processes in the human endometrium. _J. Steroid Biochem. Mol. Biol._ 120, 116–126 (2010). Article  CAS  PubMed  Google Scholar  * Burney, R.O. _et

al_. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. _Endocrinology_ 148, 3814–3826 (2007). Article 

CAS  PubMed  Google Scholar  * Savaris, R.F. _et al_. Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles. _J.

Clin. Endocrinol. Metab._ 96, 1737–1746 (2011). Article  CAS  PubMed  PubMed Central  Google Scholar  * Burney, R.O. & Giudice, L.C. Pathogenesis and pathophysiology of endometriosis.

_Fertil. Steril._ 98, 511–519 (2012). Article  CAS  PubMed  Google Scholar  * Young, S.L. & Lessey, B.A. Progesterone function in human endometrium: clinical perspectives. _Semin.

Reprod. Med._ 28, 5–16 (2010). Article  CAS  PubMed  Google Scholar  * Straub, R.H. The complex role of estrogens in inflammation. _Endocr. Rev._ 28, 521–574 (2007). Article  CAS  PubMed 

Google Scholar  * Flickinger, G.L., Elsner, C., Illington, D.V., Muechler, E.K. & Mikhail, G. Estrogen and progesterone receptors in the female genital tract of humans and monkeys. _Ann.

NY Acad. Sci._ 286, 180 (1977). Article  CAS  PubMed  Google Scholar  * Sanborn, B.M., Kuo, K.S. & Held, B. Estrogen and progestogen binding site concentrations in human endometrium and

cervix throughout the menstrual cycle and in tissue from women taking oral contraceptives. _J. Steroid Biochem._ 9, 951 (1978). Article  CAS  PubMed  Google Scholar  * Brenner, R.M., West,

N.B. & McClellan, M.C. Esrogen and progestin receptors in the reproductive tract of male and female primates. _Biol. Reprod._ 42, 11–19 (1990). Article  CAS  PubMed  Google Scholar  *

Savouret, J.F. _et al_. The progesterone receptor. Biological effects of progestins and antiprogestins. _Hum. Reprod._ 9 (Suppl. 1), 7 (1994). Article  CAS  PubMed  Google Scholar  * Bur,

M.E., Greene, G.L. & Press, M.F. Estrogen receptor localization in formalin-fixed, paraffin-embedded endometrium and endometriotic tissues. _Int. J. Gynecol. Pathol._ 6, 140 (1987).

Article  CAS  PubMed  Google Scholar  * Garcia, E. _et al_. Use of immunoctyochemistry of progesterone and estrogen receptors for endometrial dating. _J. Clin. Endocrinol. Metab._ 67, 80

(1988). Article  CAS  PubMed  Google Scholar  * Lessey, B.A., Killam, A.P., Metzger, D.A., Haney, A.F., Greene, G.L. & McCarty, K.S. Immunohistochemical analysis of human uterine

estrogen and progesterone receptors throughout the menstrual cycle. _J. Clin. Endocrinol. Metab._ 67, 334–340 (1988). Article  CAS  PubMed  Google Scholar  * Masuzawa, H., Badokhon, N.H.,

Nakayama, K., Konishi, I., Nikaido, T. & Fujii, S. Failure of down-regulation of estrogen receptors and progesterone receptors after medroxyprogesterone acetate administration for

endometrial hyperplasias. _Cancer_ 74, 2321 (1994). Article  CAS  PubMed  Google Scholar  * Okulicz, W.C. & Balsamo, M. A double immunofluorescent method for simultaneous analysis of

progesterone-dependent changes in proliferation and the oestrogen receptor in endometrium of rhesus monkeys. _J. Reprod. Fertil._ 99, 545 (1993). Article  CAS  PubMed  Google Scholar  *

Slayden, O.D. & Brenner, R.M. Hormonal regulation and localization of estrogen, progestin and androgen receptors in the endometrium of nonhuman primates: effects of progesterone receptor

antagonists. _Arch. Histol. Cytol._ 67, 393–409 (2004). Article  CAS  PubMed  Google Scholar  * Perrot-Applanat, M., Deng, M., Fernandez, H., Lelaidier, C., Meduri, G. & Bouchard, P.

Immunohistochemical localization of estradiol and progesterone receptors in human uterus throughout pregnancy: expression in endometrial blood vessels. _J. Clin. Endocrinol. Metab._ 78, 216

(1994). CAS  PubMed  Google Scholar  * Hou, Q., Paria, B.C., Mui, C., Dey, S.K. & Gorski, J. Immunolocalization of estrogen receptor protein in the mouse blastocyst during normal and

delayed implantation. _Proc. Natl. Acad. Sci. USA_ 93, 2376 (1996). Article  CAS  PubMed  PubMed Central  Google Scholar  * Brenner, R.M., McClellan, M.C., West, N.B., Novy, M.J., Haluska,

G.J. & Sternfeld, M.D. Estrogen and progestin receptors in the macaque endometrium. _Ann. NY Acad. Sci._ 622, 149 (1991). Article  CAS  PubMed  Google Scholar  * Geisert, R.D., Brenner,

R.M., Moffatt, R.J., Harney, J.P., Yellin, T. & Bazer, F.W. Changes in oestrogen receptor protein, mRNA expression and localization in the endometrium of cyclic and pregnant gilts.

_Reprod. Fertil. Dev._ 5, 247 (1993). Article  CAS  PubMed  Google Scholar  * Slayden, O.D. & Brenner, R.M. Hormonal regulation and localization of estrogen, progestin and androgen

receptors in the endometrium of nonhuman primates: effects of progesterone receptor antagonists. _Arch. Histol. Cytol._ 67, 393–409 (2004). Article  CAS  PubMed  Google Scholar  * Mead, R.A.

& Eroschenko, V.P. Changes in uterine estrogen and progesterone receptors during delayed implantation and early implantation in the spotted skunk. _Biol. Reprod._ 53, 827 (1995).

Article  CAS  PubMed  Google Scholar  * Das, N., Wang, J. & Dey, S.K. Uterine preparation for implantation in the mouse is associated with coordinate expression of estrogen-responsive

finger protein and estrogen receptor. _Mol. Reprod. Dev._ 46, 499 (1997). Article  CAS  PubMed  Google Scholar  * Cherny, R.A., Salamonsen, L.A. & Findlay, J.K. Immunocytochemical

localization of oestrogen receptors in the endometrium of the ewe. _Reprod. Fertil. Dev._ 3, 321 (1991). Article  CAS  PubMed  Google Scholar  * Aupperle, H. _et al_. Cyclical endometrial

steroid hormone receptor expression and proliferation intensity in the mare. _Equine. Vet. J._ 32, 228 (2000). Article  CAS  PubMed  Google Scholar  * Lessey, B.A. & Gorell, T.A. A

cytoplasmic estradiol receptor in the immature beagle uterus. _J. Steroid Biochem. Mol. Biol._ 13, 211–217 (1980). Article  CAS  Google Scholar  * Lessey, B.A., Wahawisan, R. & Gorell,

T.A. Hormonal regulation of cytoplasmic estrogen and progesterone receptors in the beagle uterus and oviduct. _Mol. Cell. Endocrinol._ 21, 17180 (1981). Article  Google Scholar  * Lessey,

B.A. _et al_. Endometrial progesterone receptors and markers of uterine receptivity in the window of implantation. _Fertil. Steril._ 65, 477–483 (1996). Article  CAS  PubMed  Google Scholar

  * de Ziegler, D., Frydman, R. & Bouchard, P. Contribution of estrogen to the morphology of "secretory" endometrium? _Fertil. Steril._ 63, 1135 (1995). Article  CAS  PubMed 

Google Scholar  * Lessey, B.A., Metzger, D.A., Haney, A.F. & McCarty, K.S. Immunohistochemical analysis of estrogen and progesterone receptors in endometriosis: comparison with normal

endometrium during the menstrual cycle and the effect of medical therapy. _Fertil. Steril._ 51, 409 (1989). Article  CAS  PubMed  Google Scholar  * Bergqvist, A. & Fernî, M. Oestrogen

and progesterone receptors in endometriotic tissue and endometrium: comparison of different cycle phases and ages. _Hum. Reprod._ 8, 2211 (1993). Article  CAS  PubMed  Google Scholar  *

Nisolle, M., Casanas-Roux, F., Wyns, C., De Menten, Y., Mathieu, P.E. & Donnez, J. Immunohistochemical analysis of estrogen and progesterone receptors in endometrium and peritoneal

endometriosis: A new quantitative method. _Fertil. Steril._ 62, 751 (1994). Article  CAS  PubMed  Google Scholar  * Matsuzaki, S., Fukaya, T., Uehara, S., Murakami, T., Sasano, H. &

Yajima, A. Characterization of messenger RNA expression of estrogen receptor-‡ and -· in patients with ovarian endometriosis. _Fertil. Steril._ 73, 1219 (2000). Article  CAS  PubMed  Google

Scholar  * Lessey, B.A., Palomino, W.A., Apparao, K.B., Young, S.L. & Lininger, R.A. Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women. _Reprod. Biol.

Endocrinol._ 4 (Suppl. 1), S9 (2006). Article  PubMed  PubMed Central  CAS  Google Scholar  * O’Malley, B.W. A life-long search for the molecular pathways of steroid hormone action. _Mol.

Endocrinol._ 19, 1402–1411 (2005). Article  PubMed  CAS  Google Scholar  * Heldring, N. _et al_. Estrogen receptors: how do they signal and what are their targets. _Physiol. Rev._ 87,

905–931 (2007). Article  CAS  PubMed  Google Scholar  * Couse, J.F. & Korach, K.S. Contrasting phenotypes in reproductive tissues of female estrogen receptor null mice. _Ann. NY Acad.

Sci._ 948, 1–8 (2001). Article  CAS  PubMed  Google Scholar  * Krikun, G. _et al_. Endometrial endothelial cell steroid receptor expression and steroid effects on gene expression. _J. Clin.

Endocrinol. Metab._ 90, 1812–1818 (2005). Article  CAS  PubMed  Google Scholar  * Bulun, S.E. _et al_. Role of estrogen receptor-beta in endometriosis. _Semin. Reprod. Med._ 30, 39–45

(2012). Article  CAS  PubMed  PubMed Central  Google Scholar  * Plante, B.J. _et al_. G protein-coupled estrogen receptor (GPER) expression in normal and abnormal endometrium. _Reprod. Sci._

19, 684–693 (2012). Article  CAS  PubMed  PubMed Central  Google Scholar  * Korach, K.S. _et al_. Update on animal models developed for analyses of estrogen receptor biological activity.

_J. Steroid Biochem. Mol. Biol._ 86, 387–391 (2003). Article  CAS  PubMed  Google Scholar  * Krege, J.H. _et al_. Generation and reproductive phenotypes of mice lacking estrogen receptor

beta. _Proc. Natl. Acad. Sci. USA_ 95, 15677–15682 (1998). Article  CAS  PubMed  PubMed Central  Google Scholar  * Otto, C. _et al_. GPR30 does not mediate estrogenic responses in

reproductive organs in mice. _Biol. Reprod._ 80, 34–41 (2009). Article  CAS  PubMed  Google Scholar  * Boonyaratanakornkit, V. & Edwards, D.P. Receptor mechanisms of rapid extranuclear

signalling initiated by steroid hormones. _Essays Biochem._ 40, 105–120 (2004). Article  CAS  PubMed  Google Scholar  * Gori, I., Pellegrini, C., Staedler, D., Russell, R., Jan, C. &

Canny, G.O. Tumor necrosis factor-alpha activates estrogen signaling pathways in endometrial epithelial cells via estrogen receptor alpha. _Mol. Cell. Endocrinol._ 345, 27–37 (2011). Article

  CAS  PubMed  Google Scholar  * Hammes, S.R. & Levin, E.R. Minireview: recent advances in extranuclear steroid receptor actions. _Endocrinology_ 152, 4489–4495 (2011). Article  CAS 

PubMed  PubMed Central  Google Scholar  * Salamonsen, L.A. & Woolley, D.E. Menstruation: induction by matrix metalloproteinases and inflammatory cells. _J. Reprod. Immunol._ 44, 1–27

(1999). Article  CAS  PubMed  Google Scholar  * Su, E.J. _et al_. Estrogen receptor-beta mediates cyclooxygenase-2 expression and vascular prostanoid levels in human placental villous

endothelial cells. _Am. J. Obstet. Gynecol._ 200, 427. e1-8 (2009). Article  PubMed  CAS  Google Scholar  * Warning, J.C., McCracken, S.A. & Morris, J.M. A balancing act: mechanisms by

which the fetus avoids rejection by the maternal immune system. _Reproduction_ 141, 715–724 (2011). Article  CAS  PubMed  Google Scholar  * Madak-Erdogan, Z. & Katzenellenbogen, B.S.

Aryl hydrocarbon receptor modulation of estrogen receptor alpha-mediated gene regulation by a multimeric chromatin complex involving the two receptors and the coregulator RIP140. _Toxicol.

Sci._ 125, 401–411 (2012). Article  CAS  PubMed  Google Scholar  * Brosens, J.J. & Parker, M.G. Gene expression: oestrogen receptor hijacked. _Nature_ 423, 487–488 (2003). Article  CAS 

PubMed  Google Scholar  * Thiruchelvam, U., Dransfield, I., Saunders, P.T. & Critchley, H.O. The importance of the macrophage within the human endometrium. _J. Leukoc. Biol._ 93, 217–225

(2012). Article  PubMed  CAS  Google Scholar  * Salamonsen, L.A. & Woolley, D.E. Menstruation: induction by matrix metalloproteinases and inflammatory cells. _J. Reprod. Immunol._ 44, 1

(1999). Article  CAS  PubMed  Google Scholar  * Henriet, P., Gaide Chevronnay, H.P. & Marbaix, E. The endocrine and paracrine control of menstruation. _Mol. Cell. Endocrinol._ 358,

197–207 (2012). Article  CAS  PubMed  Google Scholar  * McEwan, M., Lins, R.J., Munro, S.K., Vincent, Z.L., Ponnampalam, A.P. & Mitchell, M.D. Cytokine regulation during the formation of

the fetal-maternal interface: focus on cell-cell adhesion and remodelling of the extra-cellular matrix. _Cytokine Growth Factor Rev._ 20, 241–249 (2009). Article  CAS  PubMed  Google

Scholar  * Paule, S., Li, Y. & Nie, G. Cytoskeletal remodelling proteins identified in fetal-maternal interface in pregnant women and rhesus monkeys. _J. Mol. Histol._ 42, 161–166

(2011). Article  CAS  PubMed  Google Scholar  * Sodin-Semrl, S., Taddeo, B., Tseng, D., Varga, J. & Fiore, S. Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix

metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. _J. Immunol._ 164, 2660–2666 (2000). Article  CAS  PubMed 

Google Scholar  * Wu, Y. _et al_. A lipoxin A4 analog ameliorates blood-brain barrier dysfunction and reduces MMP-9 expression in a rat model of focal cerebral ischemia-reperfusion injury.

_J. Mol. Neurosci._ 46, 483–491 (2012). Article  CAS  PubMed  Google Scholar  * Chen, Q.H., Zhou, W.D., Pu, D.M., Huang, Q.S., Li, T. & Chen, Q.X. 15-Epi-lipoxin A(4) inhibits the

progression of endometriosis in a murine model. _Fertil. Steril._ 93, 1440–1447 (2010). Article  CAS  PubMed  Google Scholar  * Xu, Z., Zhao, F., Lin, F., Chen, J. & Huang, Y. Lipoxin A4

inhibits the development of endometriosis in mice: the role of anti-inflammation and anti-angiogenesis. _Am. J. Reprod. Immunol._ 67, 491–497 (2012). Article  CAS  PubMed  Google Scholar  *

Loke, Y.W., King, A. & Burrows, T.D. Decidua in human implantation. _Hum. Reprod._ 10 (Suppl 2), 14–21 (1995). Article  CAS  PubMed  Google Scholar  * Nagamatsu, T. & Schust, D.J.

The immunomodulatory roles of macrophages at the maternal-fetal interface. _Reprod. Sci._ 17, 209–218 (2010). Article  CAS  PubMed  Google Scholar  * Ariel, A. & Serhan, C.N. New lives

given by cell death: macrophage differentiation following their encounter with apoptotic leukocytes during the resolution of inflammation. _Front. Immunol._ 3, 4 (2012). PubMed  PubMed

Central  Google Scholar  * Maderna, P. _et al_. FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. _FASEB J._

24, 4240–4249 (2010). Article  CAS  PubMed  Google Scholar  * Serhan, C.N. & Savill, J. Resolution of inflammation: the beginning programs the end. _Nat. Immunol._ 6, 1191–1197 (2005).

Article  CAS  PubMed  Google Scholar  * Mathis, D. & Shoelson, S.E. Immunometabolism: an emerging frontier. _Nat. Rev. Immunol._ 11, 81 (2011). Article  CAS  PubMed  PubMed Central 

Google Scholar  * Ribas, V. _et al_. Myeloid-specific estrogen receptor alpha deficiency impairs metabolic homeostasis and accelerates atherosclerotic lesion development. _Proc. Natl. Acad.

Sci. USA_ 108, 16457–16462 (2011). Article  CAS  PubMed  PubMed Central  Google Scholar  * Shapiro, H., Lutaty, A. & Ariel, A. Macrophages, meta-inflammation, and immuno-metabolism.

_ScientificWorldJournal_ 11, 2509–2529 (2011). Article  PubMed  PubMed Central  CAS  Google Scholar  * Tsuji, I., Ami, K., Miyazaki, A., Hujinami, N. & Hoshiai, H. Benefit of diagnostic

laparoscopy for patients with unexplained infertility and normal hysterosalpingography findings. _Tohoku J. Exp. Med._ 219, 39–42 (2009). Article  PubMed  Google Scholar  * Nakagawa, K.,

Ohgi, S., Horikawa, T., Kojima, R., Ito, M. & Saito, H. Laparoscopy should be strongly considered for women with unexplained infertility. _J. Obstet. Gynaecol. Res._ 33, 665–670 (2007).

Article  PubMed  Google Scholar  * Sampson, J.A. Metastatic or embolic endometriosis, due to menstrual dissemination of endometrial tissue into venous circulation. _Am. J. Pathol._ 3, 93–110

(1927). CAS  PubMed  PubMed Central  Google Scholar  * Gashaw, I., Hastings, J.M., Jackson, K.S., Winterhager, E. & Fazleabas, A.T. Induced endometriosis in the baboon (Papio anubis)

increases the expression of the proangiogenic factor CYR61 (CCN1) in eutopic and ectopic endometria. _Biol. Reprod._ 74, 1060–1066 (2006). Article  CAS  PubMed  Google Scholar  * Hastings,

J.M., Jackson, K.S., Mavrogianis, P.A. & Fazleabas, A.T. The estrogen early response gene FOS is altered in a baboon model of endometriosis. _Biol. Reprod._ 75, 176–182 (2006). Article 

CAS  PubMed  Google Scholar  * D’Hooghe, T.M., Debrock, S., Hill, J.A. & Meuleman, C. Endometriosis and subfertility: is the relationship resolved? _Semin. Reprod. Med._ 21, 243–254

(2003). Article  PubMed  Google Scholar  * Jackson, K.S., Brudney, A., Hastings, J.M., Mavrogianis, P.A., Kim, J.J. & Fazleabas, A.T. The altered distribution of the steroid hormone

receptors and the chaperone immunophilin FKBP52 in a baboon model of endometriosis is associated with progesterone resistance during the window of uterine receptivity. _Reprod. Sci._ 14,

137–150 (2007). Article  CAS  PubMed  Google Scholar  * Wang, C., Mavrogianis, P.A. & Fazleabas, A.T. Endometriosis is associated with progesterone resistance in the baboon (_Papio

anubis_) oviduct: evidence based on the localization of oviductal glycoprotein 1 (OVGP1). _Biol. Reprod._ 80, 272–278 (2008). Article  PubMed  CAS  Google Scholar  * Jasper, M.J., Tremellen,

K.P. & Robertson, S.A. Primary unexplained infertility is associated with reduced expression of the T-regulatory cell transcription factor Foxp3 in endometrial tissue. _Mol. Hum.

Reprod._ 12, 301–308 (2006). Article  CAS  PubMed  Google Scholar  * Robertson, S.A., Guerin, L.R., Moldenhauer, L.M. & Hayball, J.D. Activating T regulatory cells for tolerance in early

pregnancy - the contribution of seminal fluid. _J. Reprod. Immunol._ 83, 109–116 (2009). Article  CAS  PubMed  Google Scholar  * Bulun, S.E. Endometriosis. _N. Engl. J. Med._ 360, 268–279

(2009). Article  CAS  PubMed  Google Scholar  * May, K. & Becker, C.M. Endometriosis and angiogenesis. _Minerva Ginecol._ 60, 245–254 (2008). CAS  PubMed  Google Scholar  * Augoulea, A.,

Alexandrou, A., Creatsa, M., Vrachnis, N. & Lambrinoudaki, I. Pathogenesis of endometriosis: the role of genetics, inflammation and oxidative stress. _Arch. Gynecol. Obstet._ 286,

99–103 (2012). Article  CAS  PubMed  Google Scholar  * Salama, S.A. _et al_. Effect of tumor necrosis factor-{alpha} on estrogen metabolism and endometrial cells: potential physiological and

pathological relevance. _J. Clin. Endocrinol. Metab._ 94, 285–293 (2009). Article  CAS  PubMed  Google Scholar  * Chuang, P.C., Lin, Y.J., Wu, M.H., Wing, L.Y., Shoji, Y. & Tsai, S.J.

Inhibition of CD36-dependent phagocytosis by prostaglandin E2 contributes to the development of endometriosis. _Am. J. Pathol._ 176, 850–860 (2010). Article  CAS  PubMed  PubMed Central 

Google Scholar  * Bacci, M. _et al_. Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of

disease. _Am. J. Pathol._ 175, 547–556 (2009). Article  CAS  PubMed  PubMed Central  Google Scholar  * Smith, K.A., Pearson, C.B., Hachey, A.M., Xia, D.L. & Wachtman, L.M. Alternative

activation of macrophages in rhesus macaques (_Macaca mulatta_) with endometriosis. _Comp. Med._ 62, 303–310 (2012). CAS  PubMed  PubMed Central  Google Scholar  * Li, Y. _et al_.

Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2. _Oncogene_ 30, 3887–3899 (2011). Article  CAS  PubMed  Google Scholar  * Carson, D.D. _et

al_. Embryo implantation. _Dev. Biol._ 223, 217–237 (2000). Article  CAS  PubMed  Google Scholar  * van Mourik, M.S., Macklon, N.S. & Heijnen, C.J. Embryonic implantation: cytokines,

adhesion molecules, and immune cells in establishing an implantation environment. _J. Leukoc. Biol._ 85, 4–19 (2009). Article  CAS  PubMed  Google Scholar  * Donaghay, M. & Lessey, B.A.

Uterine receptivity: alterations associated with benign gynecological disease. _Semin. Reprod. Med._ 25, 461–475 (2007). Article  CAS  PubMed  Google Scholar  * Montrone, M., Martorelli, D.,

Rosato, A. & Dolcetti, R. Retinoids as critical modulators of immune functions: new therapeutic perspectives for old compounds. _Endocr. Metab. Immune Disord. Drug Targets_ 9, 113–131

(2009). Article  CAS  PubMed  Google Scholar  * Nagy, L., Szanto, A., Szatmari, I. & Szeles, L. Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid

environment and shape their immune response. _Physiol. Rev._ 92, 739–789 (2012). Article  CAS  PubMed  Google Scholar  * Fazleabas, A.T., Donnelly, K.M., Mavrogianis, P.A. & Verhage,

H.G. Retinol-binding protein in the baboon ( Papio anubis ) uterus: Immunohistochemical characterization and gene expression. _Biol. Reprod._ 50, 1207 (1994). Article  CAS  PubMed  Google

Scholar  * Ito, K. _et al_. Retinoid receptors in the human endometrium and its disorders: a possible modulator of 17 beta-hydroxysteroid dehydrogenase. _J. Clin. Endocrinol. Metab._ 86,

2721–2727 (2001). CAS  PubMed  Google Scholar  * Lei, J., Hasegawa, H., Matsumoto, T. & Yasukawa, M. Peroxisome proliferator-activated receptor alpha and gamma agonists together with

TGF-beta convert human CD4+CD25- T cells into functional Foxp3+ regulatory T cells. _J. Immunol._ 185, 7186–7198 (2010). Article  CAS  PubMed  Google Scholar  * Klotz, L. _et al_. The

nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. _J. Exp. Med._ 206, 2079–2089 (2009). Article  CAS 

PubMed  PubMed Central  Google Scholar  * Ye, Z.J. _et al_. Generation and differentiation of IL-17-producing CD4+ T cells in malignant pleural effusion. _J. Immunol._ 185, 6348–6354 (2010).

Article  CAS  PubMed  Google Scholar  * Motohashi, E. _et al_. Regulatory expression of lipoxin A4 receptor in physiologically estrus cycle and pathologically endometriosis. _Biomed.

Pharmacother._ 59, 330–338 (2005). Article  CAS  PubMed  Google Scholar  * Chen, Q., Zhou, W., Pu, D., Li, Z., Huang, Q. & Chen, Q. The inhibitory effect of 15-R-LXA4 on experimental

endometriosis. _Eur. J. Obstet. Gynecol. Reprod. Biol._ 145, 200–204 (2009). Article  CAS  PubMed  Google Scholar  * Bruner-Tran, K.L., Eisenberg, E., Yeaman, G.R., Anderson, T.A., McBean,

J. & Osteen, K.G. Steroid and cytokine regulation of matrix metalloproteinase expression in endometriosis and the establishment of experimental endometriosis in nude mice. _J. Clin.

Endocrinol. Metab._ 87, 4782–4791 (2002). Article  CAS  PubMed  Google Scholar  * Walker, J. _et al_. Lipoxin a4 increases survival by decreasing systemic inflammation and bacterial load in

sepsis. _Shock_ 36, 410–416 (2011). Article  CAS  PubMed  Google Scholar  * Wu, J. _et al_. Lipoxin A4 inhibits the production of proinflammatory cytokines induced by beta-amyloid _in vitro_

and _in vivo_. _Biochem. Biophys. Res. Commun._ 408, 382–387 (2011). Article  CAS  PubMed  Google Scholar  * Herington, J.L., Glore, D.R., Lucas, J.A., Osteen, K.G. & Bruner-Tran, K.L.

Dietary fish oil supplementation inhibits formation of endometriosis-associated adhesions in a chimeric mouse model. _Fertil. Steril._ 99, 543–550 (2012). Article  PubMed  PubMed Central 

CAS  Google Scholar  * Bulun, S.E. _et al_. Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis. _Semin. Reprod. Endocrinol._ 28, 36–43 (2010).

Article  CAS  Google Scholar  * Igarashi, T.M. _et al_. Reduced expression of progesterone receptor-B in the endometrium of women with endometriosis and in cocultures of endometrial cells

exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. _Fertil. Steril._ 84, 67–74 (2005). Article  CAS  PubMed  Google Scholar  * Tan, H., Yi, L., Rote, N.S., Hurd, W.W. & Mesiano, S.

Progesterone receptor-a and -B have opposite effects on proinflammatory gene expression in human myometrial cells: implications for progesterone actions in human pregnancy and parturition.

_J. Clin. Endocrinol. Metab._ 97, E719–E730 (2012). Article  CAS  PubMed  PubMed Central  Google Scholar  * Yang, H., Zhou, Y., Edelshain, B., Schatz, F., Lockwood, C.J. & Taylor, H.S.

FKBP4 is regulated by HOXA10 during decidualization and in endometriosis. _Reproduction_ 143, 531–538 (2012). Article  CAS  PubMed  Google Scholar  * Hirota, Y. _et al_. Deficiency of

immunophilin FKBP52 promotes endometriosis. _Am. J. Pathol._ 173, 1747–1757 (2008). Article  CAS  PubMed  PubMed Central  Google Scholar  * Pavone, M.E., Reierstad, S., Sun, H., Milad, M.,

Bulun, S.E. & Cheng, Y.H. Altered retinoid uptake and action contributes to cell survival in endometriosis. _J. Clin. Endocrinol. Metab._ 95, E300–E309 (2010). Article  PubMed  PubMed

Central  Google Scholar  * Lee, J. _et al_. Differentially expressed genes implicated in unexplained recurrent spontaneous abortion. _Int. J. Biochem. Cell Biol._ 39, 2265–2277 (2007).

Article  CAS  PubMed  Google Scholar  * Wieser, F., Wu, J., Shen, Z., Taylor, R.N. & Sidell, N. Retinoic acid suppresses growth of lesions, inhibits peritoneal cytokine secretion, and

promotes macrophage differentiation in an immunocompetent mouse model of endometriosis. _Fertil. Steril._ 97, 1430–1437 (2012). Article  CAS  PubMed  PubMed Central  Google Scholar  *

Sawatsri, S., Desai, N., Rock, J.A. & Sidell, N. Retinoic acid suppresses interleukin-6 production in human endometrial cells. _Fertil. Steril._ 73, 1012 (2009). Article  Google Scholar

  * Tseng, J.F. _et al_. Interleukin-6 secretion _in vitro_ is up-regulated ectopic and eutopic endometrial stromal cells from women with endometriosis. _J. Clin. Endocrinol. Metab._ 81,

1118 (1996). CAS  PubMed  Google Scholar  * Trukhacheva, E., Lin, Z., Reierstad, S., Cheng, Y.H., Milad, M. & Bulun, S.E. ER{beta} regulates ER{alpha} expression in stromal cells derived

from ovarian endometriosis. _J. Clin. Endocrinol. Metab._ 94, 615–622 (2008). Article  PubMed  PubMed Central  CAS  Google Scholar  * Pellegrini, C. _et al_. The expression of estrogen

receptors as well as GREB1, c-MYC, and Cyclin D1, estrogen-regulated genes implicated in proliferation, is increased in peritoneal endometriosis. _Fertil. Steril._ 98, 1200–1208 (2012).

Article  CAS  PubMed  Google Scholar  * Burns, K.A., Rodriguez, K.F., Hewitt, S.C., Janardhan, K.S., Young, S.L. & Korach, K.S. Role of estrogen receptor signaling required for

endometriosis-like lesion establishment in a mouse model. _Endocrinology_ 153, 3960–3971 (2012). Article  CAS  PubMed  PubMed Central  Google Scholar  * May, K.E., Conduit-Hulbert, S.A.,

Villar, J., Kirtley, S., Kennedy, S.H. & Becker, C.M. Peripheral biomarkers of endometriosis: a systematic review. _Hum. Reprod. Update_ 16, 651–674 (2010). Article  CAS  PubMed  PubMed

Central  Google Scholar  * May, K.E., Villar, J., Kirtley, S., Kennedy, S.H. & Becker, C.M. Endometrial alterations in endometriosis: a systematic review of putative biomarkers. _Hum.

Reprod. Update_ 17, 637–653 (2011). Article  CAS  PubMed  Google Scholar  * Vodolazkaia, A. _et al_. Evaluation of a panel of 28 biomarkers for the non-invasive diagnosis of endometriosis.

_Hum. Reprod._ 27, 2698–2711 (2012). Article  CAS  PubMed  Google Scholar  * Noble, L.S., Simpson, E.R., Johns, A. & Bulun, S.E. Aromatase expression in endometriosis. _J. Clin.

Endocrinol. Metab._ 81, 174–179 (1996). CAS  PubMed  Google Scholar  * Bukulmez, O., Hardy, D.B., Carr, B.R., Word, R.A. & Mendelson, C.R. Inflammatory status influences aromatase and

steroid receptor expression in endometriosis. _Endocrinology_ 149, 1190–1204 (2008). Article  CAS  PubMed  Google Scholar  * Attar, E. _et al_. Prostaglandin E2 via steroidogenic factor-1

coordinately regulates transcription of steroidogenic genes necessary for estrogen synthesis in endometriosis. _J. Clin. Endocrinol. Metab._ 94, 623–631 (2009). Article  CAS  PubMed  Google

Scholar  * Bulun, S.E. _et al_. Progesterone resistance in endometriosis: link to failure to metabolize estradiol. _Mol. Cell. Endocrinol._ 248, 94–103 (2006). Article  CAS  PubMed  Google

Scholar  * Khoufache, K., Michaud, N., Harir, N., Kibangou Bondza, P. & Akoum, A. Anomalies in the inflammatory response in endometriosis and possible consequences: a review. _Minerva

Endocrinol._ 37, 75–92 (2012). CAS  PubMed  Google Scholar  * Park, J.S., Lee, J.H., Kim, M., Chang, H.J., Hwang, K.J. & Chang, K.H. Endometrium from women with endometriosis shows

increased proliferation activity. _Fertil. Steril._ 92, 1246–1249 (2009). Article  CAS  PubMed  Google Scholar  * Critchley, H.O.D., Tong, S., Cameron, S.T., Drudy, T.A., Kelly, R.W. &

Baird, D.T. Regulation of bcl-2 gene family members in human endometrium by antiprogestin administration _in vivo_. _J. Reprod. Fertil._ 115, 389 (1999). Article  CAS  PubMed  Google Scholar

  * Zhang, H., Zhao, X., Liu, S., Li, J., Wen, Z. & Li, M. 17betaE2 promotes cell proliferation in endometriosis by decreasing PTEN via NFkappaB-dependent pathway. _Mol. Cell.

Endocrinol._ 317, 31–43 (2010). Article  CAS  PubMed  Google Scholar  * Lousse, J.C., Van Langendonckt, A., Defrere, S., Ramos, R.G., Colette, S. & Donnez, J. Peritoneal endometriosis is

an inflammatory disease. _Front Biosci (Elite Ed)_ 4, 23–40 (2012). Article  Google Scholar  * Hornung, D., Bentzien, F., Wallwiener, D., Kiesel, L. & Taylor, R.N. Chemokine bioactivity

of RANTES in endometriotic and normal endometrial stromal cells and peritoneal fluid. _Mol. Hum. Reprod._ 7, 163–168 (2001). Article  CAS  PubMed  Google Scholar  * Bersinger, N.A.,

Gunthert, A.R., McKinnon, B., Johann, S. & Mueller, M.D. Dose-response effect of interleukin (IL)-1beta, tumour necrosis factor (TNF)-alpha, and interferon-gamma on the _in vitro_

production of epithelial neutrophil activating peptide-78 (ENA-78), IL-8, and IL-6 by human endometrial stromal cells. _Arch. Gynecol. Obstet._ 283, 1291–1296 (2011). Article  CAS  PubMed 

Google Scholar  * Hirata, T. _et al_. Interleukin-17F increases the secretion of interleukin-8 and the expression of cyclooxygenase 2 in endometriosis. _Fertil. Steril._ 96, 113–117 (2011).

Article  CAS  PubMed  Google Scholar  * Ebert, A.D., Bartley, J. & David, M. Aromatase inhibitors and cyclooxygenase-2 (COX-2) inhibitors in endometriosis: new questions—old answers?

_Eur. J. Obstet. Gynecol. Reprod. Biol._ 122, 144–150 (2005). Article  CAS  PubMed  Google Scholar  * Attar, E. & Bulun, S.E. Aromatase and other steroidogenic genes in endometriosis:

translational aspects. _Hum. Reprod. Update_ 12, 49–56 (2006). Article  CAS  PubMed  Google Scholar  * Yamanaka, K. _et al_. Dienogest inhibits aromatase and cyclooxygenase-2 expression and

prostaglandin E(2) production in human endometriotic stromal cells in spheroid culture. _Fertil. Steril._ 97, 477–482 (2012). Article  CAS  PubMed  Google Scholar  * Roberts, M., Luo, X.

& Chegini, N. Differential regulation of interleukins IL-13 and IL-15 by ovarian steroids, TNF-alpha and TGF-beta in human endometrial epithelial and stromal cells. _Mol. Hum. Reprod._

11, 751–760 (2005). Article  CAS  PubMed  Google Scholar  * Pan, Q., Luo, X., Toloubeydokhti, T. & Chegini, N. The expression profile of micro-RNA in endometrium and endometriosis and

the influence of ovarian steroids on their expression. _Mol. Hum. Reprod._ 13, 797–806 (2007). Article  CAS  PubMed  Google Scholar  * Ohlsson Teague, E.M. _et al_. MicroRNA-regulated

pathways associated with endometriosis. _Mol. Endocrinol._ 23, 265–275 (2009). Article  PubMed  PubMed Central  CAS  Google Scholar  * Grechukhina, O. _et al_. A polymorphism in a let-7

microRNA binding site of KRAS in women with endometriosis. _EMBO Mol. Med._ 4, 206–217 (2012). Article  CAS  PubMed  PubMed Central  Google Scholar  * Kumar, M. _et al_. Let-7

microRNA-mediated regulation of IL-13 and allergic airway inflammation. _J. Allergy Clin. Immunol._ 128, 1077–1085 e1-10 (2011). Article  CAS  PubMed  Google Scholar  * Somigliana, E.,

Vigano, P., Benaglia, L., Busnelli, A., Vercellini, P. & Fedele, L. Adhesion prevention in endometriosis: a neglected critical challenge. _J. Minim. Invasive. Gynecol._ 19, 415–421

(2012). Article  PubMed  Google Scholar  * Vercellini, P., Somigliana, E., Vigano, P., Abbiati, A., Daguati, R. & Crosignani, P.G. Endometriosis: current and future medical therapies.

_Best Pract. Res. Clin. Obstet. Gynaecol._ 22, 275–306 (2008). Article  PubMed  Google Scholar  * McDonnell, D.P. & Wardell, S.E. The molecular mechanisms underlying the pharmacological

actions of ER modulators: implications for new drug discovery in breast cancer. _Curr. Opin. Pharmacol._ 10, 620–628 (2010). Article  CAS  PubMed  PubMed Central  Google Scholar  Download

references ACKNOWLEDGEMENTS Studies described here were funded by the Swiss National Science Foundation (grant number 310030-12076), Roche and Novartis Research Foundations as well as by the

Department of Gynecology and Obstetrics, Centre Hospitalier Universitaire Vaudois (to GOC) and by the NIH R01HD067721 (to BAL). AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Geneva

Foundation for Medical Education and Research, Versoix, Switzerland G O Canny * University of South Carolina School of Medicine—Greenville, Greenville, SC, USA B A Lessey Authors * G O Canny

View author publications You can also search for this author inPubMed Google Scholar * B A Lessey View author publications You can also search for this author inPubMed Google Scholar

CORRESPONDING AUTHOR Correspondence to G O Canny. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no conflict of interest. POWERPOINT SLIDES POWERPOINT SLIDE FOR FIG. 1

POWERPOINT SLIDE FOR FIG. 2 RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Canny, G., Lessey, B. The role of Lipoxin A4 in endometrial biology and

endometriosis. _Mucosal Immunol_ 6, 439–450 (2013). https://doi.org/10.1038/mi.2013.9 Download citation * Received: 04 July 2012 * Accepted: 16 January 2013 * Published: 13 March 2013 *

Issue Date: May 2013 * DOI: https://doi.org/10.1038/mi.2013.9 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a

shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative